This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global gene therapy market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the gene therapy market. The secondary sources used for this study include the US Food and Drug Administration (FDA), European Medicines Agency (EMA), ClinicalTrials.gov, World Health Organization (WHO), National Human Genome Research Institute (NHGRI), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), BioPharm International, ScienceDirect, Purple Book, Personalized Medicine Coalition, White Papers, and Factiva, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global gene therapy market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Bottom-up approach were used to estimate and validate the total size of the gene therapy market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
-
A list of the major global players operating in the gene therapy market was generated.
-
The revenues generated from their gene therapy product have been determined through annual reports, and secondary sources (including paid database)
-
The products were mapped as per the segments of the market. Percentage shares, splits were determined based on the revenue contributed to each of the segments. This was verified using secondary sources and by industry experts
-
All assumptions, approaches and individual shares/revenue estimates were validated through expert interviews.
Global Gene therapy Market Size: Bottom-up Approach and Top Down Approach
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Gene therapy can be defined as a technique that modifies a person’s genes to treat or cure disease (Source: US FDA). This market includes gene therapy products of various types, such as viral vectors, plasmid DNA, patient-derived cellular gene therapy products, and human gene editing technology-based products. The report covers marketed as well as pipeline (Phase II and Phase III) gene therapy products which are going to launch over the forecast period. Furthermore, major therapeutic area of gene therapy covers neurology which covers rare and genetic neuromuscular disease, oncology and hematology which includes hemophilia, and other blood related conditions, as most of therapies are already launched and some are in pipeline for these therapeutic areas.
Stakeholders
-
Manufacturers and distributors of gene therapy products
-
Pharmaceutical and biotechnology companies
-
Contract research organizations (CROs)
-
Contract Development & Manufacturing Organizations (CDMOs)
-
Market research and consulting firms
-
R&D centers
-
Academic & research institutes
-
Regulatory Agencies
-
Health insurers and payers
-
Venture Capitalists
-
Government Organizations
-
Industry Associations and Professional Societies
-
Private & government-funding organizations
Report Objectives
-
To define, describe, and forecast the gene therapy market based on therapy type, vector, gene type, therapeutic area, delivery method, route of administration, end user, and region
-
To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
-
To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall gene therapy market
-
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
-
To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
-
To profile the key players in the gene therapy market and comprehensively analyze their product portfolios, market positions, and core competencies
-
To track and analyze competitive developments in the gene therapy market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
-
To benchmark players within the gene therapy market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy
NORTH AMERICA HAS THE HIGHEST MARKET SHARE IN 2024
THE US IS FASTEST GROWING MARKET IN THE REGION
Anna
Dec, 2022
Can you elaborate on some of the lucrative growth opportunities key players can look forward to in the Gene Therapy Market?.
Dwane
Dec, 2022
What will be the expected revenue growth by 2029 in the global Gene Therapy Market?.